93 related articles for article (PubMed ID: 17034119)
1. Discovery of phenyl acetic acid substituted quinolines as novel liver X receptor agonists for the treatment of atherosclerosis.
Hu B; Collini M; Unwalla R; Miller C; Singhaus R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Resmini C; Liu QY; Feingold I; Huselton C; Azam F; Farnegardh M; Enroth C; Bonn T; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
J Med Chem; 2006 Oct; 49(21):6151-4. PubMed ID: 17034119
[TBL] [Abstract][Full Text] [Related]
2. Further modification on phenyl acetic acid based quinolines as liver X receptor modulators.
Hu B; Jetter J; Kaufman D; Singhaus R; Bernotas R; Unwalla R; Quinet E; Savio D; Halpern A; Basso M; Keith J; Clerin V; Chen L; Liu QY; Feingold I; Huselton C; Azam F; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2007 May; 15(10):3321-33. PubMed ID: 17391964
[TBL] [Abstract][Full Text] [Related]
3. Biarylether amide quinolines as liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Ullrich J; Fletcher H; Quinet E; Nambi P; Unwalla R; Wilhelmsson A; Goos-Nilsson A; Farnegardh M; Wrobel J
Bioorg Med Chem; 2009 Feb; 17(4):1663-70. PubMed ID: 19162487
[TBL] [Abstract][Full Text] [Related]
4. Discovery and SAR of cinnolines/quinolines as liver X receptor (LXR) agonists with binding selectivity for LXRbeta.
Hu B; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wihelmsson A; Nambi P; Wrobel J
Bioorg Med Chem; 2009 May; 17(10):3519-27. PubMed ID: 19394832
[TBL] [Abstract][Full Text] [Related]
5. Carboxylic acid based quinolines as liver X receptor modulators that have LXRbeta receptor binding selectivity.
Hu B; Quinet E; Unwalla R; Collini M; Jetter J; Dooley R; Andraka D; Nogle L; Savio D; Halpern A; Goos-Nilsson A; Wilhelmsson A; Nambi P; Wrobel J
Bioorg Med Chem Lett; 2008 Jan; 18(1):54-9. PubMed ID: 18023179
[TBL] [Abstract][Full Text] [Related]
6. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype.
Lund EG; Peterson LB; Adams AD; Lam MH; Burton CA; Chin J; Guo Q; Huang S; Latham M; Lopez JC; Menke JG; Milot DP; Mitnaul LJ; Rex-Rabe SE; Rosa RL; Tian JY; Wright SD; Sparrow CP
Biochem Pharmacol; 2006 Feb; 71(4):453-63. PubMed ID: 16325781
[TBL] [Abstract][Full Text] [Related]
7. Discovery and implementation of transcriptional biomarkers of synthetic LXR agonists in peripheral blood cells.
DiBlasio-Smith EA; Arai M; Quinet EM; Evans MJ; Kornaga T; Basso MD; Chen L; Feingold I; Halpern AR; Liu QY; Nambi P; Savio D; Wang S; Mounts WM; Isler JA; Slager AM; Burczynski ME; Dorner AJ; LaVallie ER
J Transl Med; 2008 Oct; 6():59. PubMed ID: 18925943
[TBL] [Abstract][Full Text] [Related]
8. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRbeta.
Molteni V; Li X; Nabakka J; Liang F; Wityak J; Koder A; Vargas L; Romeo R; Mitro N; Mak PA; Seidel HM; Haslam JA; Chow D; Tuntland T; Spalding TA; Brock A; Bradley M; Castrillo A; Tontonoz P; Saez E
J Med Chem; 2007 Aug; 50(17):4255-9. PubMed ID: 17665897
[TBL] [Abstract][Full Text] [Related]
9. Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
Hu B; Unwalla RJ; Goljer I; Jetter JW; Quinet EM; Berrodin TJ; Basso MD; Feingold IB; Nilsson AG; Wilhelmsson A; Evans MJ; Wrobel JE
J Med Chem; 2010 Apr; 53(8):3296-304. PubMed ID: 20350005
[TBL] [Abstract][Full Text] [Related]
10. Liver X receptor (LXR)-beta regulation in LXRalpha-deficient mice: implications for therapeutic targeting.
Quinet EM; Savio DA; Halpern AR; Chen L; Schuster GU; Gustafsson JA; Basso MD; Nambi P
Mol Pharmacol; 2006 Oct; 70(4):1340-9. PubMed ID: 16825483
[TBL] [Abstract][Full Text] [Related]
11. 4-(3-Aryloxyaryl)quinoline sulfones are potent liver X receptor agonists.
Bernotas RC; Singhaus RR; Kaufman DH; Travins JM; Ullrich JW; Unwalla R; Quinet E; Evans M; Nambi P; Olland A; Kauppi B; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(1):209-12. PubMed ID: 19932617
[TBL] [Abstract][Full Text] [Related]
12. Quinoline-3-carboxamide containing sulfones as liver X receptor (LXR) agonists with binding selectivity for LXRbeta and low blood-brain penetration.
Hu B; Bernotas R; Unwalla R; Collini M; Quinet E; Feingold I; Goos-Nilsson A; Wilhelmsson A; Nambi P; Evans M; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):689-93. PubMed ID: 19962892
[TBL] [Abstract][Full Text] [Related]
13. Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure.
Jaye MC; Krawiec JA; Campobasso N; Smallwood A; Qiu C; Lu Q; Kerrigan JJ; De Los Frailes Alvaro M; Laffitte B; Liu WS; Marino JP; Meyer CR; Nichols JA; Parks DJ; Perez P; Sarov-Blat L; Seepersaud SD; Steplewski KM; Thompson SK; Wang P; Watson MA; Webb CL; Haigh D; Caravella JA; Macphee CH; Willson TM; Collins JL
J Med Chem; 2005 Aug; 48(17):5419-22. PubMed ID: 16107141
[TBL] [Abstract][Full Text] [Related]
14. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis.
Wrobel J; Steffan R; Bowen SM; Magolda R; Matelan E; Unwalla R; Basso M; Clerin V; Gardell SJ; Nambi P; Quinet E; Reminick JI; Vlasuk GP; Wang S; Feingold I; Huselton C; Bonn T; Farnegardh M; Hansson T; Nilsson AG; Wilhelmsson A; Zamaratski E; Evans MJ
J Med Chem; 2008 Nov; 51(22):7161-8. PubMed ID: 18973288
[TBL] [Abstract][Full Text] [Related]
15. A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a).
Menke JG; Macnaul KL; Hayes NS; Baffic J; Chao YS; Elbrecht A; Kelly LJ; Lam MH; Schmidt A; Sahoo S; Wang J; Wright SD; Xin P; Zhou G; Moller DE; Sparrow CP
Endocrinology; 2002 Jul; 143(7):2548-58. PubMed ID: 12072387
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway.
Qiu G; Hill JS
J Cardiovasc Pharmacol; 2008 Apr; 51(4):388-95. PubMed ID: 18427282
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of 4-(3-biaryl)quinoline sulfones as potent liver X receptor agonists.
Ullrich JW; Morris R; Bernotas RC; Travins JM; Jetter J; Unwalla R; Quinet E; Nambi P; Feingold I; Huselton C; Enroth C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 May; 20(9):2903-7. PubMed ID: 20382019
[TBL] [Abstract][Full Text] [Related]
18. Pitavastatin effect on ATP binding cassette A1-mediated lipid efflux from macrophages: evidence for liver X receptor (LXR)-dependent and LXR-independent mechanisms of activation by cAMP.
Zanotti I; Potì F; Favari E; Steffensen KR; Gustafsson JA; Bernini F
J Pharmacol Exp Ther; 2006 Apr; 317(1):395-401. PubMed ID: 16415093
[TBL] [Abstract][Full Text] [Related]
19. 3-(3-Aryloxyaryl)imidazo[1,2-a]pyridine sulfones as liver X receptor agonists.
Singhaus RR; Bernotas RC; Steffan R; Matelan E; Quinet E; Nambi P; Feingold I; Huselton C; Wilhelmsson A; Goos-Nilsson A; Wrobel J
Bioorg Med Chem Lett; 2010 Jan; 20(2):521-5. PubMed ID: 20005711
[TBL] [Abstract][Full Text] [Related]
20. Discovery and structure-activity relationship studies of indole derivatives as liver X receptor (LXR) agonists.
Bakir F; Kher S; Pannala M; Wilson N; Nguyen T; Sircar I; Takedomi K; Fukushima C; Zapf J; Xu K; Zhang SH; Liu J; Morera L; Schneider L; Sakurai N; Jack R; Cheng JF
Bioorg Med Chem Lett; 2007 Jun; 17(12):3473-9. PubMed ID: 17416521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
